We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Expression Pathology Signs Biomarker Discovery Deal with Digene
News

Expression Pathology Signs Biomarker Discovery Deal with Digene

Expression Pathology Signs Biomarker Discovery Deal with Digene
News

Expression Pathology Signs Biomarker Discovery Deal with Digene

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Expression Pathology Signs Biomarker Discovery Deal with Digene"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Expression Pathology Inc. has announced that it has entered into research collaboration with Digene Corporation to identify cancer protein biomarkers in archived tissue using Expression Pathology’s proprietary Microproteomics Biomarker Discovery platform.

Under the terms of the agreement, Expression Pathology will employ its Liquid Tissue™ MS Protein Prep reagents with LC MS/MS mass spectrometry to identify proteins in microdissected formalin-fixed tissue of known pathology and clinical history.

Advertisement